Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.
Launched by NEURONETRIX, INC. · Dec 27, 2007
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
Patients who have a current diagnosis of mild-moderate dementia and suspected of having Alzheimer's disease (AD) along with cognitively normal age-matched controls will be recruited for this study. The Alzheimer's subjects either will have had a complete clinical and neuropsychiatric workup or will have those tests performed during the study.
Both groups, AD and controls will be asked to listen to a series of sounds and press a button on a handheld control box when a target sound is heard. The COGNISION(TM) headset on each subject's head will then record the electrical signals during this ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria for AD:
- • Age 60 to 85
- • Mild to moderate diagnosis of Alzhiemer's disease
- Inclusion Criteria for Control:
- • Age 60 to 85
- • Cognitively healthy with no complaints
- Exclusion Criteria:
- • Subjects with advanced AD and severe impairment (CDR \> 2, MMSE less than 15)
- • Neurological disorders such as stroke, Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumor, delirium, or psychiatric disorder other than depression (e.g. schizophrenia)
- • Subjects with life threatening illnesses and subjects with significant hearing or visual impairments
- • Subjects with a current prescription for psychoactive pharmaceuticals
About Neuronetrix, Inc.
NeuroNetrix, Inc. is a pioneering clinical trial sponsor dedicated to advancing neurotechnology and improving patient outcomes through innovative research and development. The company specializes in the design and execution of clinical trials that focus on neurological disorders and cognitive health, leveraging cutting-edge methodologies and robust data analytics. Committed to scientific rigor and ethical standards, NeuroNetrix collaborates with leading healthcare professionals and institutions to deliver groundbreaking solutions that enhance diagnostic and therapeutic approaches in neurology. With a patient-centric focus, the company aims to transform the landscape of neurological care through its comprehensive research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Trial Officials
Charles D Smith, M.D.
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials